Consensus Molecules Associated with Parkinson's Disease.
Neurol Int 2026 Jan 27; 18(2).

Abstract

Parkinson's disease (PD) has been associated with some types of food and drugs. Here, we query PubMed for the association of PD with foods and drugs, using a list of 217,776 compounds derived from the Human Metabolome Database (HMDB). To calculate associations, a Python script was developed to query PubMed for co-citations of PD with each compound, and adjust this count for compound abundance. Notably, PD is found to be associated with small-molecule drugs, adjunctive therapies, contraindicated drugs, diagnostic agents, biomarkers, conditional essential molecules, and inducers. Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%). Diagnostic agents include FP-CIT (60%) and beta-CIT (43%). Biomarkers include 3-methoxytyrosine (48%) and homovanillic acid (12%). Endogenous cofactors include tetrahydrobiopterin (4%) and Coenzyme Q10 (4%). Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential endogenous cofactors associated with PD and emphasizes rational directions for investigation in PD.

Authors+Show Affiliations

Eyal SAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Alfasi SAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Ben Zaken KAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Sawaid IOAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Segev LAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Mesfin SAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Frankel PAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Ezzy RAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Saha-Detroja THurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Madhavan SAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Bloch N0009-0005-7886-4049Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Polis B0000-0002-3496-8250Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Samson AO0000-0001-7436-3515Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

41745708